Treatment regimens for patients with chronic lymphocytic leukaemia (CLL) increasingly include targeted agents (such as the inhibitor of BTK ibrutinib or the anti-CD20 antibodies rituximab and obinutuzumab) rather than cytotoxic agents (for example, the DNA alkylating agents chlorambucil and bendamustine). New evidence supporting benefit with targeted therapies was presented at the 2018 Annual Meeting of the American Society of Hematology (ASH).
05.02.2019 | Chronische lymphatische Leukämie | International Research Highlight | Online-Artikel